Publications by authors named "Yu Ha"

Claim this Profile
C
COVID-19 vaccine hesitancy in Chinese residents: A national cross-sectional survey in the community setting.
Tianshuo Zhao, Xianming Cai, Sihui Zhang, Mingting Wang, Linyi Chen, Yu Ha

Hum Vaccin Immunother· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to: Blind Spots in REZILIENT-1: Does Post-platinum Zipalertinib Address Needs in Epidermal Growth Factor Receptor ex20ins+ Non-Small Cell Lung Cancer?
Zofia Piotrowska, Helena A Yu

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TROPION-Lung15: a randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients with -mutated advanced non-small cell lung cancer and whose disease has progressed on prior osimertinib.
Daniel Shao-Weng Tan, Ernest Nadal, Parneet Cheema, Yi-Long Wu, Myung-Ju Ahn

Ther Adv Med Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Dose-Escalation Trial Combining Olaparib and Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer.
Andreas Rimner, Benjamin H Lok, Daphna Y Gelblum, Rupesh R Kotecha, Jacob Y Shin, Narek Shaverdian, Charles B Simone, Michael D Offin, Zhigang Zhang, Abraham J Wu, Charles M Rudin

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Treatment for Opioid Use Disorder in Pregnancy and Its Impact on Birth Outcomes.
Ashley A Leech, Shawn Garbett, Hanxuan A Yu, Elizabeth McNeer, Rashmi Bharadwaj, Michael J Ward, Mark N Ellingham

JAMA Pediatr· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes with neoadjuvant osimertinib and/or chemotherapy in patients with EGFR-mutant resectable non-small cell lung cancers.
Prashasti Agrawal, Julia Rotow, Gaetano Rocco, William Travis, Eduardo Ortiz, Jamie E Chaft

Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of home and clinical blood pressure variability on arteriosclerosis and metabolic indicators: a prospective multicenter registry study.
Ha Young Yu, Jung-Joon Cha, Dong-Hyuk Cho, Mi-Na Kim, Se Won Oh

Clin Hypertens· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases.
J A Wilcox, M Y Jeng, S Tischfield, J S Y Sui, D Nemirovsky

Ann Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report.
Xiuning Le, Christina Baik, Byoung Chul Cho, Jonathan W Riess, Zofia Piotrowska, Adrianus Johannes de Langen, Jonathan W Goldman, Brayan Merchan Ruiz

J Thorac Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases.
Monica F Chen, Jake June-Koo Lee, Noura J Choudhury, Angela B Hui, Mark Y Jeng, Lauren Schaff, Jamie E Chaft

J Thorac Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival in EGFR-Mutant Advanced NSCLC Treated With First-Line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in the United States.
Joshua K Sabari, Helena A Yu, Parthiv J Mahadevia, Yanfang Liu, Levon Demirdjian

J Thorac Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to: Comments on the Study of Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With -Mutant Lung Cancer.
Monica F Chen, Daniel Gomez, Helena A Yu

JCO Precis Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab.
Zofia Piotrowska, Antonio Passaro, Danny Nguyen, Gerrina Ruiter, Ross A Soo, Vamsidhar Velcheti, Daniel Shao-Weng Tan, Haruko Daga

J Clin Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib.
Jonathan W Riess, Adrianus J de Langen, Santiago Ponce, Sarah B Goldberg, Zofia Piotrowska, Jonathan W Goldman

JCO Precis Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lung Cancer and Cardiovascular Disease: Common Pathophysiology and Treatment-Emergent Toxicity.
Malak El-Rayes, Inbar Nardi Agmon, Christopher Yu, Nichanan Osataphan, Helena A Yu, Paaladinesh Thavendiranathan

JACC CardioOncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With -Mutant Lung Cancer Treated With Osimertinib.
Monica F Chen, Mark Y Jeng, Jennifer Ma, Prashasti Agrawal, Elizabeth Dunne, Harini Veeraraghavan

JCO Precis Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Responsiveness of different MET tumour alterations to type I and type II MET inhibitors.
Yonina R Murciano-Goroff, Valentina Foglizzo, Jason Chang, Natasha Rekhtman, Ann Elizabeth Sisk, Shaza Sayed Ahmed, Sherifah Kemigisha Muzungu, Michael F Berger, Srinivasaraghavan Kannan, Chandra S Verma

Clin Transl Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complementary modes of resistance to TKI in lung adenocarcinoma through MAPK activation and cellular plasticity.
Matthew Zatzman, Alvaro Quintanal-Villalonga, Sohrab Salehi, Nicholas Ceglia, Jake June-Koo Lee, Ojasvi Chaudhary, Ronan Chaligne, Charles M Rudin, Sohrab P Shah

bioRxiv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Podcast Discussion on the Intracranial Efficacy of Antibody-Drug Conjugates in Patients with EGFR-Mutated NSCLC with Brain Metastases.
Melissa L Johnson, Jessica J Lin, Adrienne Boire, Melin J Khandekar, Helena A Yu

Oncol Ther· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients with exon 20 insertion-mutated NSCLC.
John V Heymach, Helena A Yu, Benjamin Besse, Ying Cheng, Daniel Sw Tan

Future Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chromothripsis-Mediated Small Cell Lung Carcinoma.
Natasha Rekhtman, Sam E Tischfield, Christopher A Febres-Aldana, Jake June-Koo Lee, Jason C Chang, Chad M Vanderbilt, Anne Marie Noronha, Harsha Sridhar, Michael Offin, Michael F Berger, Charles M Rudin

Cancer Discov· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung Cancer.
Arielle Elkrief, Meagan Montesion, Smruthy Sivakumar, Caryn Hale, Anita S Bowman, Eric Chan, Natasha Rekhtman, Umesh Bhanot, Mithat Gönen, Charles M Rudin, Chad M Vanderbilt

J Clin Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets.
Monica F Chen, Soo-Ryum Yang, Jessica J Tao, Antoine Desilets, Eli L Diamond, Michael Offin

Clin Cancer Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leptomeningeal Metastasis in the Era of CNS-Penetrant Tyrosine Kinase Inhibitor Therapy.
Mark Y Jeng, Helena A Yu

J Clin Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradation.
Alvaro Quintanal-Villalonga, Kenta Kawasaki, Esther Redin, Fathema Uddin, Swanand Rakhade, Moniquetta Shafer, Wouter R Karthaus, Yingqian A Zhan, Harsha Sridhar, Umesh K Bhanot, Michael C Haffner, Richard P Koche, Joseph M Chan, Charles M Rudin

Signal Transduct Target Ther· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis